"The company will achieve its strategic goal of HK$100 billion revenue by 2030 through comprehensive innovation and transformation driven by independent research and development and external introduction. 79 products are expected to be launched in the next three years," said Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm.

As a leading innovative R&D-driven pharmaceutical group in China, Sino Biopharm has always adhered to the three principles of "for the country, for the people and for the company" to guide its operation and development. At the recently held 2022 CEO Conference, Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm, and Mr. Tse, Eric S Y, Chief Executive Officer of Sino Biopharm, jointly unveiled the corporate culture of Sino Biopharm,

On October 14, 2022, well-known pharmaceutical industry media E Pharmaceutical managers and China's leading independent corporate and society responsibility consulting agency BizDao Consulting jointly released the "ESG Competitiveness and ESG Investment Value List of Chinese pharmaceutical Listed Enterprises". With its excellent ESG management performance and outstanding industry competitiveness,

On November 2, Sino Biopharm (01177.HK) announced that in the third quarter of 2022, as the pandemic situation in China was under control and normal production and life order was restored, medical consumption and in-hospital treatment volume recovered significantly, and the Group timely seized the opportunity to accelerate the progress of research and development, production and sales, driving the Group to achieve rapid recovery growth in the third quarter of 2022. In the third quarter of 2022